Steve Shamah

Steve Shamah

Company: 2SeventyBio

Job title: Vice President, Oncology


Flipping the Script on the Tumor Microenvironment: Supercharging MAGEA4-Targeting T-Cells to Resist Tumor Immunosuppression 1:30 pm

We have identified a highly selective and active MAGEA4-directed, HLA-A02-restricted TCR To combat the effects of TGFβ, a potent immunosuppressive factor often coexpressed in MAGEA4+ solid tumors, we have developed CTBR12, a flip receptor that converts TGFβ activity into a proliferative T-cell activation signal Preclinical in vitro and in vivo models demonstrate potent tumor control…Read more

day: Conference Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.